Nobody has run a randomised comparison of telemedicine against in-person care for weight management. Four separate literature searches turned up one comparative dataset in the whole field, and it is a retrospective chart review at a single American centre. So the choice between a remote weight-management service, your own GP and a hospital specialist is not settled by evidence — it turns on what each route is set up to do, what the rules require of each, and what your own situation needs. This article covers all three.
Remote provision: the licence mode under which telemedicine operates in Singapore. It is the same Outpatient Medical Service licence as a clinic holds, delivered remotely.
What the evidence actually compares
One study, and its own authors say it does not settle the question.
Researchers at a US academic weight-management centre reviewed the charts of patients on weight-management medication across three groups: in-person only (69 patients), in-person followed by video (85), and video only (91). Median percent weight change over six months was −4.3% in the in-person cohort, −5.6% in the hybrid group and −5.8% in the video cohort, differences the authors report as not significant. The share reaching at least 5% weight loss was 46.4%, 55.3% and 59.3% respectively. The video cohort attended more visits — a median of five against four (Tchang 2022).
Now the limits, because they are large. The study is retrospective, single-centre and non-randomised. Of 499 eligible charts, 245 were analysed — 49% returned at six months, so more than half the eligible sample is missing from the comparison. All cohorts were predominantly white and female. The commonest medicines prescribed were metformin, a diabetes-dose semaglutide product and topiramate, not the weight-management products a reader here is likely asking about. The senior author declares extensive industry ties. And the authors' own stated conclusion is: "More investigation is required to compare telemedicine models with in-person care" (Tchang 2022).
The absence is the finding. Anyone claiming telemedicine works as well as in-person weight management — or that it works less well — is going beyond what has been measured.
What a route has to provide beyond the prescription
WHO published a global guideline on GLP-1 therapies for obesity in December 2025, and both of its recommendations bear on the route question.
The first is that GLP-1 therapies "may be used by adults, but excluding pregnant women, for the long-term treatment of obesity" — and it is a conditional recommendation. WHO grades it that way because of limited data on long-term efficacy and safety, on maintenance and discontinuation, on current costs, on health-system preparedness, and on potential equity implications. The second recommendation, made on low-certainty evidence, is that "Intensive behavioural interventions, including structured interventions involving healthy diet and physical activity, may be offered to adults living with obesity prescribed GLP-1 therapies" (WHO 2025).
Read together, those say the international position is a qualified yes with named reservations, and that the medicine is expected to sit inside something rather than stand alone — while being clear that the evidence for the surrounding programme is itself low-certainty. The useful question to put to any route is therefore what surrounds the prescription, and who is accountable for it. That is a question about the programme rather than the delivery mode, and it is where the three routes differ most.
What licensed telemedicine is required to do
This part is not a matter of opinion, and it is unusually specific.
Before providing any service remotely, a licensee must ascertain the patient's identity, contact information and location; tell the patient not to seek essential life-saving measures remotely; and identify the personnel providing the service and their role. A licensee must not provide a service remotely to a first-time patient unless it is through real-time two-way interactive audiovisual communications. Video consultations must be real-time and two-way, conducted in a place that is closed and private, with sufficient lighting and equipment. A licensee must hold written guidelines on which patients are suited to remote care. And where a practitioner is of the opinion that a patient needs treatment, care or a physical examination that cannot be carried out remotely, the licensee must make alternative arrangements and inform the patient (OMS Regulations).
The joint regulator circular adds the working detail: a real-time video consultation is conducted for first-time patients to establish the doctor-patient relationship; "Teleconsultations must not be provided solely by way of self-service, text-only questions"; medicines should not be prescribed "just by getting a patient to fill-up a questionnaire"; practitioners must assess whether the patient type or condition is within the limits of their own competence; and "Patients or conditions which require a more comprehensive and detailed physical examination for adequate clinical assessment should not be managed via teleconsultation" (Circular 87/2024).
Singapore's medical regulator sets the standard the care is measured against, and does so without softening the comparison: telemedicine "is not equal to conventional in-person care and has to be provided in a responsible manner", a doctor must "endeavour to provide the same quality and standard of care as in-person medical care" and otherwise "must state the limitations" of their opinion, and patients must be given enough information about telemedicine's limitations to consent to it (SMC).
Older national guidance points the same way. Singapore's 2015 telemedicine guidelines state that a face-to-face evaluation "where reasonably practical must be done before or very soon after commencement of Telemedicine services", and that where face-to-face is not reasonably practical, delivering care exclusively by telemedicine is permitted (MOH 2015). The statutory licensing regime now runs through the Healthcare Services Act and its regulations, so the 2015 document is context rather than the governing instrument.
What this looks like from the patient's side is described in what happens at a GLP-1 video consultation, and what gets asked is covered in what your doctor will ask you.
What a GP consultation gives you that a remote weight service does not
Three things, and they are worth naming plainly.
A physical examination. Some findings need hands, a stethoscope or a room. The regulations recognise this directly by requiring alternative arrangements where an examination cannot be carried out remotely (OMS Regulations), and the joint circular says such cases should not be managed by teleconsultation at all (Circular 87/2024).
One record in one place. A GP who has seen you for years holds a longer history than any assessment can reconstruct, and is the person best placed to notice a change that has nothing to do with weight.
Care for everything else. A weight-management service treats weight. If you have type 2 diabetes, that condition is managed by your own doctor — GetLean is a weight-management service and does not treat diabetes. The same applies to blood pressure, lipids, thyroid disease and anything else that needs ongoing management. If you are on a weight-management medicine, your GP should know.
None of this makes one route better than another. They are set up to do different jobs, and for many people the answer involves both.
When a specialist is the route
Two situations, and Singapore publishes thresholds for one of them.
MOH's own primary-care protocol sets out when bariatric surgery is offered. For Asian patients, the stated indication is clinically severe obesity: "BMI ≥37.5 kg/m² OR BMI ≥32.5 kg/m² with conditions like Type 2 DM, hypertension, lipid disorder, fatty liver, polycystic ovarian syndrome, obstructive sleep apnoea, and metabolic syndrome". The same protocol tiers referrals, placing BMI 32.5 to 37.5 with comorbidities, and BMI ≥37.5 with or without them, in its highest-priority segment (MOH protocol).
That is a decision for a surgical service and the doctor making the referral. We are not the route to it, and this article makes no recommendation about it. How surgery compares with medication on the published evidence is covered in every weight-loss option in Singapore, compared honestly.
The second situation is a condition that needs specialist management in its own right — an endocrine disorder, a sleep disorder, a psychiatric condition. Weight is often part of those pictures and is rarely the whole of them.
Which BMI number applies to you
Singapore runs two scales at the same time, and both are correct.
The national obesity guideline classifies the local adult population as overweight from a BMI of 23.0 and obese from 27.5, with waist-circumference action points above 90 cm in men and 80 cm in women (HPB-MOH 2016). MOH's primary-care protocol separately sets medication indications at "BMI ≥30 kg/m² with or without obesity-related complications or risk factors, OR When BMI is 27.5 – 29.9 kg/m² among Asians with co-morbidities or complications of obesity" (MOH protocol).
So a person can sit above the national classification for obesity and still be below a treatment threshold, and neither document is wrong. The research behind the lower local classification is covered in why Asian BMI thresholds are lower. Which number applies in your case is a clinical judgement, and it is not settled by a calculator.
What none of the routes changes
The medicine is prescription-only whichever door you come through, the standard of care is the same, and the part that determines what you keep is the same too.
Substantial weight loss costs lean mass regardless of who prescribed it and regardless of whether the consultation happened in a room or on a screen. Protein and resistance training are the modifiable part of that, and no route supplies them by itself. That is the question worth asking of any provider on any route — how to choose a GLP-1 clinic sets out the rest of them.
Individual circumstances vary, and which route suits you is a decision to make with a doctor who has assessed you.
Common questions
Is telehealth as effective as seeing a doctor in person for weight loss?
Nobody has run the trial that would answer that. The only comparative dataset is a retrospective single-centre review of 245 US patients in which six-month weight change did not differ significantly between in-person, video and mixed care — and whose own authors state more investigation is required (Tchang 2022).
What must a licensed telemedicine provider in Singapore do?
Ascertain your identity, contact details and location before consulting; see a first-time patient by real-time two-way audiovisual consultation; hold written guidelines on who is suited to remote care; and arrange in-person care where a physical examination is needed (OMS Regulations).
When should you see a GP instead?
When something needs examining, when the question is about a condition other than weight, or when you want one record in one place. The regulations require a telemedicine licensee to make alternative arrangements where a physical examination cannot be carried out remotely (OMS Regulations).
At what point does surgery become the conversation?
Singapore's MOH primary-care protocol sets bariatric-surgery indications for Asian patients at BMI ≥37.5, or ≥32.5 with a condition such as type 2 diabetes, hypertension, lipid disorder, fatty liver, polycystic ovarian syndrome, obstructive sleep apnoea or metabolic syndrome (MOH protocol). That is a decision for a surgical service, not for us.
Which BMI number decides whether I am eligible?
There is more than one, and both are correct. Singapore's national obesity guideline classifies overweight from 23 and obesity from 27.5 (HPB-MOH 2016), while MOH's primary-care protocol sets medication indications at BMI ≥30, or 27.5–29.9 with comorbidity (MOH protocol). Which applies to you is a clinical judgement.